Regentis Biomaterials Ltd. (RGNT) Stock

Healthcare · Medical Instruments & Supplies · Member of Other US Stocks

Regentis Biomaterials Ltd. (RGNT) closed at USD 1.51 on 2026-10-14, a change of -79.9 % over the past year, with a market capitalization of USD 10.89M.

Regentis Biomaterials Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Regentis Biomaterials Ltd. key figures

Previous close

USD 1.51 (2026-10-14)

1-year change

-79.9 %

Market cap

USD 10.89M

Enterprise value

USD 1.96M

P/E ratio (trailing)

-0.66

P/E ratio (forward)

n/a

EPS (trailing)

-2.34

EPS (forward)

n/a

PEG ratio

n/a

Price to book

1.42

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.07

Employees

n/a

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Regentis Biomaterials Ltd.

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Regentis Biomaterials Ltd. and compare it with other stocks.